Magnus Persson, Chairman
Magnus Persson, MD PhD Associate Professor (Karolinska Institutet), brings 20 years of international experience from leadership in life science innovation, development and financing and has been a partner in two life sciences venture capital firms, HealthCap and The Column Group.
Magnus Persson has a long experience from medicine, life sciences and biotech financing including leading development teams of Phase II and III programs in the pharmaceutical Industry, and has founded, and led private as well as public biotech and medtech companies as Chairman of the Board, Board Director and CEO in the Nordic Countries, Europe and USA. Magnus is currently CEO of Karolinska Institutet Holding AB.
Richard Cowburn, PhD, currently holds the position as Program Manager at the Karolinska Institutet Innovation Office with responsibility for establishing collaborations with industrial partners. Richard Cowburn is a Neuroscientist specialized in Alzheimer’s disease. He previously held a strategic position at AstraZeneca where he was responsible for providing direction to the Neurology project pipeline. This included delivering novel targets from both in-house research and from external collaborations and in-licensing opportunities.
Pirkko Thamsen, PhD, is Director of Innovation Office, Uppsala University. Pirkko Tamsen held clinical project leader positions at Astra (now AstraZeneca) and Kabi/Pharmacia (now Pfizer) in the years 1989-1999, was CEO and co-owner of SEDOC PM in 1999-2007 and CEO of a succession of start-up companies based on research discoveries and innovations from Karolinska Institutet, Stockholm, and Uppsala University between 2008 and 2013.
Maris Hartmanis, PhD from the Royal Institute of Technology in Stockholm. Over the years, Maris Hartmanis has held numerous leading positions in both global companies and startups. Between 2010 and 2014, he was CEO of BioPhausia and Medivir. Maris Hartmanis has also founded MetaXen and Gyros and raised over a 1 billion SEK in venture capital. Currently, he is involved in the re-organization of the Karolinska University Hospital.
Irene Fialka has a PhD degree in Molecular Biology from Vienna University. She joined INiTS in 2004, has helped numerous entrepreneurs shape and build successful business since then and was appointed CEO in 2012. Dr Fialka is also Vice-Chairman and Member of Management Board of Wings4Innovation – a collaborative project of 17 Austrian academic research institutions that aims at establishing an independent Translational Research Centre in the field of Life Sciences in Austria to transfer breakthrough basic research into commercially valuable assets.
Per Matsson, presently Chief Technology Officer at Thermo Fisher Scientific ImmunoDiagnostic Division has a PhD in cell biology and more than 25 years of international life science industry experience in R&D, Medical & Regulatory affairs, IPR and business development including strategy and M&A. After postdoctoral employment at the University of California San Francisco, he was appointed as associate professor at Uppsala University and as associate professor at Swedish Agricultural University, Veterinary Medicine.